1. Home
  2. GWRS vs AGEN Comparison

GWRS vs AGEN Comparison

Compare GWRS & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Global Water Resources Inc.

GWRS

Global Water Resources Inc.

N/A

Current Price

$8.18

Market Cap

230.7M

Sector

Utilities

ML Signal

N/A

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$7.71

Market Cap

274.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GWRS
AGEN
Founded
2003
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Water Supply
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
230.7M
274.8M
IPO Year
2008
1999

Fundamental Metrics

Financial Performance
Metric
GWRS
AGEN
Price
$8.18
$7.71
Analyst Decision
Buy
Strong Buy
Analyst Count
2
3
Target Price
$10.30
★ $26.33
AVG Volume (30 Days)
61.6K
★ 1.1M
Earning Date
11-11-2026
11-09-2026
Dividend Yield
★ 3.73%
N/A
EPS Growth
N/A
★ 100.00
EPS
0.08
★ 0.96
Revenue
$41,914,000.00
★ $42,877,086.00
Revenue This Year
$10.30
$9.64
Revenue Next Year
$0.86
N/A
P/E Ratio
$102.00
★ $7.85
Revenue Growth
8.51
★ 89.95
52 Week Low
$6.55
$2.71
52 Week High
$11.07
$10.19

Technical Indicators

Market Signals
Indicator
GWRS
AGEN
Relative Strength Index (RSI) 46.66 46.32
Support Level $7.78 $6.51
Resistance Level $9.31 $8.64
Average True Range (ATR) 0.21 0.63
MACD 0.00 -0.18
Stochastic Oscillator 63.49 14.75

Price Performance

Historical Comparison
GWRS
AGEN

About GWRS Global Water Resources Inc.

Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: